Timothy K. Andrews - 14 Nov 2021 Form 4 Insider Report for Prometheus Biosciences, Inc.

Reporting relationship: General Counsel
Issuer ticker: N/A
Reported as of: 14 Nov 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Nov 2021, 20:12:43 UTC
Source filing: View source filing
Reporting owner signature: Timothy K. Andrews

Key filing fact

Timothy K. Andrews filed Form 4 for Prometheus Biosciences, Inc. on 16 Nov 2021.

Key facts

This page summarizes Timothy K. Andrews's Form 4 filing for Prometheus Biosciences, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Nov 2021, 20:12.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RXDX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +54,132
Change %
Price: $0.000000
Shares after: 54,132
Date: 14 Nov 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 54,132
Exercise price: $36.32
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option will vest on November 14, 2022, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date.